Across TCGA pan-cancer cohorts, C10orf62 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C10orf62 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher C10orf62 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C10orf62 expression acts as an unfavorable survival marker.

THCA, PRAD, and CHOL are the cancer types where C10orf62 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.049	0.841	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: C10orf62 tumor-vs-normal RNA expression · all C10orf62 data types